Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
نویسندگان
چکیده
منابع مشابه
Fulvestrant in postmenopausal women with advanced breast cancer.
PURPOSE Patients with hormone-sensitive breast cancer who have responded to tamoxifen (TAM) may receive additional benefit from a second endocrine agent after progression or relapse after TAM therapy. Fulvestrant (FVT; Faslodex; i.m. injection, ICI 182,780; AstraZeneca Pharmaceuticals, Wilmington, DE) was developed as a selective antagonist of estrogen. In postmenopausal women, FVT is reported ...
متن کاملPalbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
BACKGROUND Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer. METHODS This phase 3 study involved 521 patients with advanced hormone-rece...
متن کاملActivity of fulvestrant in HER2-overexpressing advanced breast cancer.
BACKGROUND Human epidermal growth factor receptor 2 (HER2) overexpression increases the aggressiveness of breast cancer cells resulting in poorer prognosis. Patients with HER2-positive disease are less responsive to endocrine therapies. Trastuzumab monotherapy results in objective responses in only approximately 15% of patients. Fulvestrant retains activity in cells overexpressing HER2 that are...
متن کاملArm symptoms and overall survival in Brazilian patients with advanced breast cancer.
INTRODUCTION Advanced breast cancer is a very frequent serious public health problem. OBJECTIVE This study aimed to analyze the prevalence of arm symptoms and overall survival in affected patients. METHODOLOGY A retrospective cohort study was accomplished in 196 women presenting with advanced breast cancer. A descriptive analysis was carried out by and overall survival probabilities were ca...
متن کاملFulvestrant for advanced male breast cancer patients: a case series.
Male breast cancer is rare and treatment recommendations are mainly extrapolated from the results of trials on women. Most breast cancers in men are estrogen receptor (ER)/ progesterone receptor (PgR) positive; as a consequence, tamoxifen remains the standard adjuvant treatment and is also the mainstay first-line treatment of advanced disease, with reported response rates varying from 25% to 80...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: New England Journal of Medicine
سال: 2018
ISSN: 0028-4793,1533-4406
DOI: 10.1056/nejmoa1810527